
Aron Simkins, MD
176 posts

Aron Simkins, MD
@dr_simkins
GI Med Onc | @ConquerCancerFd #ASCO21 Merit Award. @GWSMHS @GWCancer @UTHimres @McgovernMed alum 🇮🇱🇻🇪










Pancreatic cancer has one of the most suppressive tumor microenvironments in oncology. But two pancreatic cancer results dropped today. Both matter. 1. BioNTech mRNA neoantigen vaccine: nearly all responders still alive at 6 years. 98% of induced T cells were de novo — the immune system learned to see a cancer it had always been blind to. 2. Daraxonrasib: 47% ORR, 92% disease control as first-line monotherapy. KRAS G12D, undruggable for 40 years, finally has a drug. Different mechanisms. Same disease. Both working. <13% of patients survive 5 years. That number is about to change. great day for science! 🔥




The chants heard yesterday in the heart of the Jewish community in Kew Gardens, Queens, in support of Hamas were vile and deliberate acts of intimidation meant to terrorize our Jewish community. NYC and state elected officials must condemn this immediately and unequivocally. Anything less is a failure of leadership. Silence leads to action. We must say it loud and clear: HAMAS AND THEIR SUPPORTERS ARE NOT WELCOME HERE.














🚨 Resectable Gastric Cancer | #GI26 CRITICS-II answers a key question What is the best preoperative strategy when adjuvant therapy is omitted? 🧪 Trial design Three fully neoadjuvant approaches compared ➡️ Chemotherapy alone ➡️ Chemotherapy → Chemoradiotherapy ➡️ Chemoradiotherapy alone 🎯 Primary endpoint 1-year event-free survival Activity threshold ≥75% 📊 Key results ✅ CT → CRT: 1-yr EFS 84% | 1-yr OS 89% | pCR 20% ✅ CRT alone: 1-yr EFS 78% | better compliance | lower toxicity ❌ CT alone: 1-yr EFS 68% | lowest survival | higher toxicity 🧠 Clinical interpretation • Chemotherapy alone fails efficacy threshold • Total neoadjuvant therapy gives the best oncologic signal • CRT alone offers a toxicity-compliant alternative • CT → CRT emerges as the preferred backbone for phase III testing and organ-sparing strategies 📌 Take-home message In resectable gastric cancer, treatment intensification before surgery matters. Pure chemo upfront is no longer convincing. #OncoTwitter #MedTwitter #GastricCancer #GI26 @asco @oncoalert @Larvol















